Gendiag and the University of Girona have created a consortium to develop the project “Prediction of cardiovascular risk in patients with chronic renal disease”, IPT-010000-47, financed by the Ministry of Science and Innovation within the National Plan of Scientific Research, Development and Technology Innovation 2008-2011 and co-financed by the European Regional Development Fund (ERDF).
“Prediction of cardiovascular risk in patients with chronic renal disease “, IPT-010000-47, with a funded budget of €993,814.40. Project financed by the Ministry of Science and Innovation within the National Plan of Scientific Research, Development and Technology Innovation 2008-2011 and co-financed by the European Regional Development Fund (ERDF).
The Consortium formed by the biotechnology company Gendiag.exe and the University of Girona (UdG) – are developing the project ” Prediction of cardiovascular risk in patients with chronic renal disease “, (IPT-010000-47). This project is financed by the Ministry of Science and Innovation within the National Plan of Scientific Research, Development and Technology Innovation 2008-2011 and co-financed by the European Regional Development Fund (ERDF).
This ambitious project brings innovative genetic technology to the clinical practice by integrating several medical disciplines with a common public health goal of preventing cardiovascular disease from being the main cause of death in Chronic Renal Disease (CRD) patients. This project will improve the interactive cooperation between different health disciplines with the aim of educating the public and the medical community, improving current diagnostic technologies and understanding the factors that trigger cardiovascular disease in CRD patients.
One of the main challenges of developing and implementing new platforms such as this one is to understand all the processes from beginning to end. And this is not something that can be achieved by individual researchers or unidisciplinary teams. The general approach in the research of CRD is multidisciplinary and many challenges need to be handled collectively. The Gendiag.exe-CGC-UdG consortium combines the data and contacts provided by a very active pool of renowned cardiology researchers with the wide experience of a medium sized company that turns ideas into products and services.
The project will be highly beneficial for the Consortium partners because it will widen the technological positioning of genetic diagnostic tools and will establish preventive strategies for cardiovascular disease in CRD patients. This project is a milestone that represents the first step in the introduction of genetic technology based medicine in primary care.